Clinical Trial Update: Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating exemestane with or without MM-121 (seribantumab) in postmenopausal women with locally advanced or metastatic ER/PR-positive, HER2-negat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Exemestane (Exemestane)
• MM-121 (seribantumab)

Snippet

Sponsor: Merrimack Pharmaceuticals | Conditions: Her2 Negative Breast Cancer Patients | Phase 2 | Status: COMPLETED | Results posted: 2016-05-12